Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 19/20 | 0.59 |
| ▸ | BBOX1 | O75936 | 1/20 | 0.44 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.44 |
| ▸ | THRA | P10827 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | EGLN2 | Q96KS0 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2883349 | 0.84 | EGLN1 (0.63) | EGLN1THRATHRBEGLN2 | |
| SCHEMBL2881819 | 0.84 | EGLN1 (0.57) | EGLN1BBOX1FTOEGLN2 | |
| SCHEMBL1218607 | 0.83 | EGLN1 (0.79) | EGLN1 | |
| SCHEMBL2880629 | 0.83 | EGLN1 (0.59) | EGLN1THRATHRBEGLN2 | |
| SCHEMBL1218831 | 0.81 | EGLN1 (0.62) | EGLN1THRATHRB | |
| SCHEMBL1218586 | 0.81 | EGLN1 (0.66) | EGLN1 | |
| SCHEMBL2879964 | 0.80 | EGLN1 (0.51) | EGLN1THRATHRBEGLN2 | |
| SCHEMBL2888188 | 0.80 | EGLN1 (0.55) | EGLN1BBOX1FTOEGLN2 | |
| SCHEMBL1219405 | 0.80 | EGLN1 (0.70) | EGLN1EGLN2 | |
| SCHEMBL1218993 | 0.79 | EGLN1 (0.61) | EGLN1BBOX1FTO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2227232-A1 | METHODS FOR INHIBITING T HELPER CELL DIFFERENTIATION | Fibrogen, Inc. (US) | 2010-09-15 | — | — | EP | disclosed |
| US-20100144737-A1 | METHODS FOR INHIBITING T HELPER CELL DIFFERENTIATION | FIBROGEN, INC. (US) | 2010-06-10 | — | — | US | disclosed |
| WO-2009075822-A1 | METHODS FOR INHIBITING T HELPER CELL DIFFERENTIATION | FIBROGEN, INC. (US) | 2009-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144737-A1 | METHODS FOR INHIBITING T HELPER CELL DIFFERENTIATION | NFATC1, CD4, IL2 | EGLN1 238/4885BBOX1 292/4885FTO 4088/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.